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Vaccinology today is a rapidly changing specialty of medical science where new developments are regularly taking
place at short intervals. There is a need to review/revise recommendations about existing vaccines in light of recent
information. Following an IAPCOI meeting in December 2011, a draft statement was prepared and circulated among
the meeting participants to arrive at a consensus.
Objectives: To review and issue recommendations on the recent contentious issues pertaining to rotavirus, Hib, and
pneumococcal conjugate vaccines and to revise recommendations for 2012 Immunization timetable for pediatricians
in ofﬁce practice.
Recommendations: IAPCOI abolished the earlier categorization of vaccines in four categories. On rotavirus, the
committee stresses the need of having more data on disease burden in India. Further, there is a need to optimize use
of rotavirus vaccines in India to achieve higher yields in term of protective efﬁcacy. In the want of adequate data, the
committee is not able to issue any speciﬁc recommendation on the suitability of a particular rotavirus vaccine
(monovalent Vs multivalent) for the country. The committee also acknowledges a small risk of acute intussusceptions
following use of current generation of rotavirus vaccines and recommends inclusion of the history of intussusception
in the past as an absolute contraindication. The committee concludes there is no safety concerns of Hib vaccines as
reported frequently in lay media. On the disease burden of pneumococcal diseases (PD), the committee concludes
that there is need of conducting more community based studies to gather more evidence. Similarly, the data on
prevalence of different pneumococcal serotypes in the country is sparse and limited to few hospital based studies.
There is need of establishing real-time multi-site pneumococcal disease surveillance in the country. Due to scarcity of
data on the prevalence of pneumococcal serotypes and non-typeable hemophilus inﬂuenzae (NTHi) in India, it is
difﬁcult to comment on the superiority of one pneumococcal conjugate vaccine over other. The committee also
revised the recommendations for the year 2012.
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Efﬁcacy of current rotavirus vaccines in India
There are no efﬁcacy trials of the licensed rotavirus
vaccines available in India. The data from other developingal Convener, IAP Committee on Immunization, 2011-13, Mangla Hosp
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61.2% (in South Africa and Malawi).1e5 There is deﬁnite
gradient in the efﬁcacies of these vaccines when different
regions of the world are compared e highest in US and
Europe, moderate in Latin America, and low in Africa
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moderate to low vaccine efﬁcacy translates into signiﬁcant
numbers of severe rotavirus gastroenteritis cases prevented
and into signiﬁcant public health impact. More rotavirus
disease burden may be prevented in developing countries
despite lower vaccine efﬁcacy than in countries with low
rotavirus disease burden and higher vaccine efﬁcacy.9
However, considering that oral vaccines elicit diminished
immune responses or have lower efﬁcacy in developing
countries than in developed countries,10 and since India is
having history of poor performance of other oral vaccines,
notably OPV in recent past,11e13 it would not be prudent toextrapolate data from other countries having comparable
epidemiologic, economic, and demographic indices.
Administration schedule of rotavirus vaccines in
India
In a recent community-based study from Vellore, it was
noted that rotavirus infection generally occurred early in
life, levels of re-infection were high and even three natural
infections were able to provide only 79% protection against
moderate or severe disease, with no evidence of homotypic
protection as believed so far.14 Therefore, there may be
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in India, by increasing the dose or increasing the number of
doses or delaying the doses or even considering neonatal
immunization. These considerations were further supported
by the immunogenicity study of another live attenuated
human oral rotavirus vaccine 116E in Indian infants, where
administration of higher (1  104 ffu vs 1  105 ffu) and
more frequent (2 vs 3) doses resulted in more robust immune
responses.15 Consequently, the ongoing phase III efﬁcacy
trial with this strain is conducted with higher dose (105 ffu)
and a 3-dose schedule (6, 10 and 14 weeks).15 It can be
argued that one study in South Africa and Malawi with
monovalent rotavirus vaccine (RV1, marketed as Rotarix)
did not detect signiﬁcant differences in vaccine immunoge-
nicity or efﬁcacy on pooled analysis between the cohortreceiving two vaccine doses and the cohort receiving three
doses.3 However, there was a slight but non-signiﬁcant trend
toward higher seroconversion rates and vaccine efﬁcacy with
the three-dose schedule, and these differences were more
marked in South Africa (81.5 (55.1e93.7) vs 72.2
(40.4e88.3)) than in Malawi (49.7 (11.3e72.2) vs 49.2
(11.1e71.7)).3 The two-dose schedule used in this trial
was 10 and 14 weeks instead of 6 and 10 weeks.3
Administering rotavirus vaccines at younger ages could
further lower the immunogenicity of the vaccines, because
of the potential for greater interference of maternal antibody
and enhanced replication of the oral poliovirus vaccine.3
In the above African study with RV1, the researchers
accepted that the study was not powered to detect differ-
ences in dose schedule.3 Furthermore, there have been
116 Pediatric Infectious Disease 2012 JulyeSeptember; Vol. 4, No. 3 Vashishthalow seroconversion rates (58.3%; 95% CI: 48.7; 67.4) with
two doses of RV1 in comparison with three-dose schedule
of RV5 (82.4% (CI; 75; 90%)) and 116E (89.7% (42.4;
80.6%)) in immunogenicity studies in India.15e17 In the
RV1 trial, the ﬁrst dose was administered between 8 and
10 weeks (mean age e 8.7 weeks) and the second dose
between 12 and 16 weeks (mean age e 13.4 weeks).16Hence, there is no immunogenicity data for 6 and 10 weeks
administration or data on interference with simultaneous
OPV administration from India. It is important when exam-
ining immunogenicity data to point out that although sero-
conversion is not a direct proxy for efﬁcacy, it does
demonstrate that the virus is able to colonize the infant
gut and induce a robust immune response.
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rotavirus vaccines,18 most countries with high rotavirus
disease incidence or high under-5 mortality rates (where
children would particularly beneﬁt from robust protection
from rotavirus infection) have 6, 10, 14 week EPI sched-
ules. If rotavirus vaccines are to be co-administered with
OPV in a setting with an EPI vaccination schedule begin-
ning at 6 weeks of age, the second dose of RV1 may not
be sufﬁcient to provide adequate immunity against severe
rotavirus disease.18 A 2-dose schedule at 10 and 14 weeks
is also assumed to be programmatically problematic, since
this would likely result in a failure in administration of
the full course of vaccines to children in developing coun-
tries due to the restrictive upper age limit for rotavirus
vaccine administration, resulting from the approach of
attempting to avoid administration of rotavirus vaccines
during the ages when there is a heightened risk of intussus-
ceptions.18 After debating intensely, the committee thinks
that there is a need to seriously relook at the proper admin-
istration schedule of rotavirus vaccines in India in order to
achieve higher yields in term of protective efﬁcacy.Safety of rotavirus vaccines and post-marketing
surveillance data on acute intussusceptions in
India
The committee reviewed the emerging data on intussuscep-
tion related to current rotavirus vaccines following large-
scale use of these vaccines in Mexico, Brazil, Australia
and US.19e22 The post-marketing surveillance (PMS) data
from India by the manufacturers of two rotavirus vaccines
licensed in India was also reviewed.
Based on PMS data, the current rotavirus vaccines have
been associated with an increased risk of intussusceptions
(about 1e2/100,000 infants vaccinated) for a short period
after administration of the ﬁrst dose in some populations.19
This risk is 5e10 times lower than that observed with
the previously licensed vaccine (1 case per 10,000 doses).
There are no published reports on incidence/rates of
acute intussusception following rotavirus vaccination in
India. However, the PMS data (unpublished) of Indian
manufacturers revealed 13 cases of acute intussusceptions
associated (causality not yet proved) with rotavirus
vaccines administration since the launch of RV1 in India
till December 2011, and two cases following RV5 during
a ﬁve-month surveillance period (MayeSeptember 2011)
in India.
There is limited information on the incidence of intus-
susception and its risk factors in India. No large-scale trials
of rotavirus vaccines have been conducted in the country to
assess whether there is an increased risk of intussusception
associated with the vaccination. Data on background ratesof intussusception in developing countries are required to
facilitate informed decision making about use of new
rotavirus vaccines. These background rates are also needed
for estimation of the sample size needed for studies to
demonstrate safety both before and after licensure of new
rotavirus vaccines. Such population-based data are not
available in most developing countries, including India.
However, a recent study from Delhi found the incidence
of intussusception requiring hospitalization was 17.7 cases
per 100,000 infant-years of follow-up (95% CI: 5.9e41.4
cases per 100,000 infant-years).23 The study also concluded
that natural rotavirus infection did not appear to be a major
cause of intussusception in Indian infants. This incidence
appears to be lower than that reported in other middle-
and high-income countries. Another retrospective study
from a tertiary-care hospital from south India identiﬁed
31 children with deﬁnite intussusception during the study
period of 1 January 2001e30 June 2004.24
After reviewing recent data, the committee concludes
that there is deﬁnite albeit a small risk of acute intussuscep-
tions following use of current generation of rotavirus
vaccines. However, the beneﬁts of rotavirus vaccination
against severe diarrhea and death from rotavirus infection
far exceed the miniscule risk of intussusceptions. It urges
the manufacturers to actively monitor the risk of intussus-
ceptions as the usage of these vaccines is bound to go up.
This will also require strengthening of AEFI surveillance
in the country. Information about the possible risk of intus-
susceptions associated with rotavirus vaccination needs to
be communicated clearly to the national decision-makers,
healthcare providers, and parents. The committee also
stresses the need of strictly adhering to the set upper age
limits of these vaccines, i.e. the ﬁrst dose of either RV1
or RV5 should be administered between the ages of 6
weeks and 14 weeks and 6 days, and that the maximum
age for administering the last dose of either vaccine should
be 32 weeks25 of these vaccines while prescribing them in
ofﬁce practice. The committee has recommended inclusion
of the history of intussusception in the past as an absolute
contraindication for rotavirus vaccine (RV1 and RV5)
administration.
PNEUMOCOCCAL CONJUGATE VACCINES
Suitability of PCV13 vs PCV10 for Indian children
The committee studied the recent data on PCV13 and
PCV10. The committee also reviewed the reports of
PCV13 studies done worldwide on immune responses
(IgG e GMC, OPA e GMT) and boostability for the sero-
type 3 capsular antigen,26 and the immune responses
following post-primary and post-booster series against
Recommendations for IAP Immunization
Timetable, 2012
IAP Immunization Timetable, 2012
Major changes
d Polio: sequential IPV-OPV schedule is recommen-
ded for primary polio immunization in place of
combined OPV þ IPV schedule.
d Hepatitis-B: ‘Birth-6 weekse6 mo’ is recommen-
ded as most preferred schedule instead of earlier
‘0e6 weekse14 weeks’ schedule.
d Rotavirus: history of intussusception in the past is
added as an absolute contraindication for RV
vaccine administration.
d Pneumococcal: prematurity and very-low birth
weight are added as another high-risk category
for pneumococcal vaccination.
d Inﬂuenza: guidelines are provided for inﬂuenza
vaccination.
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has reviewed the interim data of COMPAS trial done in
three Latin American countries with PCV1029 and effec-
tiveness of PCV10 in Brazil.30
The committee also reviewed available data on the efﬁ-
cacy of the new serotypes in the PCV13. In England and
Wales,31 vaccine effectiveness (VE) for the new serotypes
for 2 doses under a year was 78% (95% CI: 18 to 96%)
and 77% (CI: 38e91%) for one dose over a year. VE for
7F and 19A was 76% (CI: 21e93%) and 70% (CI:
10e90%), respectively for  one dose, for serotypes 1
and 3 was 62% and 66%, respectively although conﬁdence
intervals spanned zero. IPD due to PCV13-only serotypes
halved in children under 2 years in the study period.31
The committee believes that the direct protection
rendered by the serotype included in a vaccine formulation
is deﬁnitely superior to any cross protection offered by the
unrelated serotypes even of the same group in a PCV formu-
lation. However, the committee still not convinced about the
clinical efﬁcacy of serotype 3 contained in PCV13 despite
multiple studies showing good functional immune responses
after the infant series29 and reasonably good effectiveness.31
There has been no consistent PCV13 impact on serotype 3
IPD or carriage reported so far.
Similarly, the committee still thinks that despite using
a different conjugation method (cyanylation vs reductive
amination),32 PCV10 is yet to demonstrate a better clinical
efﬁcacy (cross protection) against serotype 19A than shown
by PCV7. Though current seroprevalence of type 19A in
India is not known, but its presence is conﬁrmed by almost
all the recent studies.33e35 Since this serotype is increasing
in many other Asian countries and has got higher antimicro-
bial resistance characteristics than other serotypes,34,35 the
committee believes that protection against 19A will be crit-
ical to determine which vaccine is appropriate to use in the
country. Recent data has now shown that PCV13 provides
protection against 19A,31 while it is unknown if the pres-
ence of ‘novel’ 19F in PCV10 will provide cross protection
against 19A.36 On the other hand, the committee is
convinced about the adequate cross protection rendered
by serotype 6Be6A based on performance of PCV7 in
many European countries and US in decreasing IPDs
caused by 6A. However, the exact role and signiﬁcance
of 6C which is clearly emerging as replacement serotype
is yet to be determined.
The committee thinks that though NTHi, a co-pathogen
plays some role in the pathogenesis of mucosal disease with
Streptococcal pneumoniae, its role in childhood pneumonia
is still not proven.
After appraising in detail all the available relevant data,
the committee concludes that since there is scarcity of data
on the prevalence of pneumococcal serotypes includingserotypes 3, 6A and 19A, and non-typeable Haemophilus
inﬂuenzae (NTHi) in India, it is almost impossible to
comment on the exact superiority of one product over other.
Further, in the absence of head to head trials it is difﬁcult to
determine if either vaccine has a clear advantage over other.
Although recent publications37 state that the same few sero-
types are responsible for a large proportion of PD in all
geographic regions and new PCVs cover almost 70% of
serotypes prevailing in India, the committee believes that
it is critical to know what percentage of pneumonia, menin-
gitis and other IPDs are caused by the pneumococcal sero-
types not included in existing formulations.
Recommendations for premature and low birth
weight infants
The committee has now stressed the need of treating prema-
turity (PT) and very-low birth weight (VLBW) infants as
another high-risk category for pneumococcal vaccination.
These infants have up to 9-fold higher incidence of invasive
pneumococcal diseases (IPD) in (VLBW babies) as
compared to full size babies.38 The risk ratio for LBW
infants compared with normal birth weight infants was
2.6, and for premature infants compared with full-term
(FT) infants was 1.6. PCV must be offered to these babies
on priority basis. PCV was as immunogenic in LBW and
PT as in NBW and FT infants; the vaccine efﬁcacy for
both groups was found 100%.38
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Immunization Timetable for the year 2012 that includes
the following major changes from last year:Poliovirus immunization
In the light of remarkable achievement in the ﬁeld of polio
eradication in India over the last one year,39 the committee
has now decided to adopt a sequential IPV-OPV schedule.
This will pave the way to ultimate adoption of all-IPV
schedule in future considering the inevitable cessation of
OPV from immunization schedules owing to its safety issues
(VAPP and cVDPVs). This policy is in accordance with the
recent decision taken by GPEI where phased removal of
Sabin viruses, beginning with highest-risk (type 2) would
be undertaken.40 This will result in elimination of VDPV
type 2 in ‘parallel’ with eradication of last wild polioviruses
by switching from tOPV to bOPV for routine EPI and
campaigns. This switch will result in much early introduction
of IPV than anticipated, at least in high-risk areas for
VDPVs, to provide type 2 protection.40Why changes in polio immunization schedule
became inevitable?
d India is polio free for >1 year!!
d Type 2 WPV eradicated in 1999
d cVDPVs especially type 2 is a concern
d VAPP cannot be overlooked anymore!
d New ‘end game strategy’ announced in November
2011
d No preparations for approaching ‘end game’
New poliovirus vaccination schedule
The primary schedule:
d OPV (birth dose) þ 3 doses of IPV at 6, 10 and 14
weeks þ 2 doses of OPV at 6 & 9 months þ IPV at
15e18 months (booster) þ OPV at 5 years
The alternative schedule:
d OPV at birthþ 2 doses of IPV at 8 and 16 weeks
(i.e. 2 & 4 mo) þ OPV at 6 & 9 mo þ IPV at
15e18 mo þ OPV at 5 years
Catch-up schedule (IPV up to 5 years of age):
d IPV can be given as 3 doses; 2 doses at 2 months
interval followed by a 3rd dose after 6 monthsThere is considerable evidence to show that sequential
schedules that provide IPV ﬁrst, followed by OPV, can
prevent VAPP while maintaining the critical beneﬁts
conferred by OPV (i.e. high levels of gut immunity). Data
from several studies show that sequential schedules consider-
ably decrease the risk of VAPP.41e44 There is moderate level
of scientiﬁc evidence that sequential immunization schedules
starting with two or more doses of IPV and followed by two
or more doses of OPV (at an interval of 4e8 weeks) induce
protective immunological responses to all three poliovirus
serotypes in 90% of vaccinees.45 However, the committee
has retained the birth dose of OPV as recommended earlier.
Providing the ﬁrst OPV dose at a time when the infant is still
protected by maternally-derived antibodies may, at least
theoretically, also prevent VAPP. A birth dose of OPV is
considered necessary in countries where the risk of polio-
virus transmission is high.46The primary schedule
The committee recommends birth dose of OPV, three
primary doses of IPV at 6, 10 and 14 weeks, followed
by two doses of OPV at 6 and 9 months, another dose
(booster) of IPV at 15e18 months and OPV at 5 years.
Alternatively, two doses of IPV can be used for primary
series at 8 and 16 weeks, though this schedule is immu-
nologically superior to EPI schedule and the number of
IPV doses is reduced, but will be more cumbersome
due to extra visits and incompatibility with combination
formulations. Further, the child would be susceptible to
WPV infection for the ﬁrst two months of life consid-
ering the epidemiology of WPV in India till quite
recently.
Since IPV administered to infants in EPI schedule (i.e. 6
weeks, 10 weeks and 14 weeks) results in suboptimal sero-
conversion,46 hence, a supplementary dose of IPV is recom-
mended at 15e18 months. IPV should be given
intramuscularly (preferably) or subcutaneously and may
be offered as a component of ﬁxed combinations of
vaccines. However, the committee recommends that if
IPV is unaffordable or unavailable, the primary series
must be completed with three doses of OPV given at 6,
10, and 14 weeks. No child should be left without adequate
protection against wild poliovirus (i.e. three doses of either
vaccine). All OPV doses (mono-, bi- or trivalent) offered
through supplementary immunization activities (SIAs),
should also be provided.Catch-up schedule
IPV may be offered as ‘catch up vaccination’ for children
less than 5 years of age who have completed primary
immunization with OPV. IPV can be given as three doses;
two doses at two months interval followed by a third dose
after 6 months. This schedule will ensure a long lasting
protection against poliovirus disease.
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The committee has now recommended the following
schedule for routine Hepatitis-B vaccination in ofﬁce prac-
tice for children: the ﬁrst dose of a three-dose schedule
should be administered at birth, second dose at 6 weeks,
and third dose at 6 months (i.e. 0e6 weeke6 month).
This schedule is not only more closer to immunologically
ideal and most widely used 0e1e6 months schedule, but
also conﬁrms to latest ACIP recommendations wherein
the ﬁnal (third or fourth) dose in the Hepatitis-B vaccine
series should be administered no earlier than age 24 weeks
and at least 16 weeks after the ﬁrst dose.47 It will replace
the existing schedule of 0e6 weeke14-week. However,
the Hepatitis-B vaccine may be given through other sched-
ules, considering the programmatic implications and
logistic issues. The committee stresses the signiﬁcance
and need of birth dose.
Inﬂuenza vaccination
The committee reviewed the WHO recommendations
regarding composition of ﬂu vaccines for the southern
and northern hemisphere for use in the 2012e2013 inﬂu-
enza seasons.48,49 For the northern hemisphere, it will
contain the following strains: an A/California/7/2009
(H1N1) pdm09-like virus; an A/Victoria/361/2011
(H3N2)-like virus; and a B/Wisconsin/1/2010-like virus.48
The last two strains will be different from the last year’s
vaccine for the region however; there will be no change
in the composition of inﬂuenza vaccines for the southern
hemisphere for 2012.49 Last year, the strains were similarfor both the hemispheres. This will have impact on the
types of vaccines to be used in coming season.
As far as the inﬂuenza virus circulation in India is con-
cerned, the data since 2004 suggests a clear peaking of circu-
lation during the rainy season across the country e
‘JuneeAugust’ in north (Delhi), west (Pune) and east
(Kolkata), and ‘OctobereDecember’ in south (Chennai).50
This data is also consistent with theWHO circulation patterns
for 2010 and 2011 for India which also shows a clear peak
coinciding with the rainy season across the country. These
data illustrate the difﬁculty in having effective uniform vacci-
nation timing for a vast country like India and have implica-
tions when formulating vaccination policies. The evidence of
antigenic drifts of circulating inﬂuenza viruses in India,
together with the temporal peaks in seasonality of inﬂuenza
in different parts of the country; illustrate the need for a stag-
gered approach in vaccination timing. Hence, the best time
for offering vaccine for individuals residing in southern states
would be just before the onset of rainy season, i.e. before
October while for rest of the country, it should be before
June. Though, the committee acknowledges that this issue
is still contentious and unresolved.
This is to be noted that WHO convenes two meetings to
provide recommendations for the usage of inﬂuenza
vaccine in February and September each year. The vaccine
for the February recommendations (Northern hemisphere)
and September recommendations (Southern hemisphere)
becomes available after 6 months of each recommendation.
With the above background the vaccine that shall be avail-
able in MarcheApril 2012 (Southern hemisphere) this year
is based on the recommendation made in September 2011
which took into account the data from the past year i.e.
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season peak last year from June to August 2011). Whereas
the vaccine that shall be available in August 2012 (Northern
hemisphere, with the 2 new strains) shall be based on the
recommendation made in February 2012 which took into
account the data from the past year i.e. March 2011eFeb
2012 which means that by the time it is available in August
2012, the most of the country barring southern states may
have already passed the peak inﬂuenza activity.
In addition to this, WHO classiﬁes India under the
‘South Asia’ transmission zone of inﬂuenza circulation.
This along with summary review of the 2011 southern
hemisphere winter inﬂuenza season49 strongly points
India’s alignment with the availability of Southern hemi-
sphere vaccine (MarcheApril) to ensure we have the latest
available strains for early vaccination to prevent the peak of
circulation of Inﬂuenza in the rainy season across the
country.
(Abstracted from: Consensus Recommendations on
Immunization and IAP Immunization Timetable 2012,
Indian Pediatrics, July 2012, Vol: 49, pp: 549e565. Avail-
able from: http://www.indianpediatrics.net/july2012/549.
pdf Accessed on July 18, 2012.)CONFLICTS OF INTEREST
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